New Data Suggests Potential Reductions to Current Barriers in Continuous Glucose Monitoring Adoption
SAN DIEGO, CA – December 12, 2017
– RESEARCH ARTICLE - https://doi.org/10.2337/cd17-0053
GlySens® Incorporated today announced the publication of new data in Clinical Diabetes from two recent patient preference studies, providing further support for a proposed 1-year, fully implanted CGM device, with no skin-attached components, currently in development.
According to the data, adult participants and parents of children with diabetes, most frequently sited four factors when deciding to employ CGM: 1) to improve glycemic control (83%), 2) lower A1C (54%), 3) to avoid hypoglycemia (53%) and 4) physician recommendation (42%). Among participants who had never used CGM, key impediments for not trying were 1) cost, 2) having a device attached to the body, and 3) expectations of discomfort when wearing. Interestingly, current and past Adult CGM users confirmed many of these expectations, reporting having problems sometimes or often with the appearance of CGM on the body, discomfort while wearing, insertion pain and skin irritation. Parents of children reported these same issues with greater frequency than adults. “These data suggest that certain people with diabetes are willing (at least initially) to tolerate obtrusive features because of their tremendous motivation to improve their health” said Robert Engler, MD. “It is clear, with our survey of over 1,000 individuals, that a CGM system which eliminates the obtrusiveness of on-body components would enjoy significant up-take among the general patient population.”
Glucose control is key to preventing both short-term and long-term complications of diabetes. A 1% reduction in A1C results in a reduction in the risk of long-term complications like stroke, heart disease, eye damage and kidney disease reduces by 40%.1
A fully implanted CGM sensor with minimal maintenance paired with an external display device, could offer an unobtrusive tool for uncompromised glucose management. The long-term, Eclipse® ICGM® is designed to empower individuals with diabetes by providing the information they need, while freeing them to live life on their own terms.
Eclipse, ICGM and GlySens are trademarks of GlySens Incorporated registered in the U.S. Patent and Trademark Office.
Caution – INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL LAW TO INVESTIGATIONAL USE.1
The post-trial monitoring results: 10 years follow up: Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359:1577-1589.